Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

Alexandra M Nanzer; Jaideep Dhariwal; Joanne Kavanagh; Andrew Hearn; Mariana Fernandes; Louise Thomson; Cris Roxas; Linda Green; Grainne D'Ancona; Sangita Agarwal; Brian D Kent; David J Jackson

doi:10.1183/23120541.00451-2020

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

ERJ Open Res. 2020 Nov 10;6(4):00451-2020. doi: 10.1183/23120541.00451-2020. eCollection 2020 Oct.

Authors

Alexandra M Nanzer^{1

2}, Jaideep Dhariwal¹, Joanne Kavanagh^{1

2}, Andrew Hearn^{1

2}, Mariana Fernandes¹, Louise Thomson¹, Cris Roxas¹, Linda Green¹, Grainne D'Ancona¹, Sangita Agarwal³, Brian D Kent¹, David J Jackson^{1

2}

Affiliations

¹ Guy's and St Thomas' NHS Foundation Trust, Thoracic Medicine, Guy's Severe Asthma Service, London, UK.
² School of Immunology & Microbial Sciences, King's College London, London, UK.
³ Dept of Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Abstract

Benralizumab reduces oral corticosteroid requirements in patients with EGPA and leads to improved patient-reported outcome measures https://bit.ly/2GI0vhf.